RAPID FORSURE ONE STEP MULTIPLE DRUG (UP TO 6) SCREEN TEST DEVICE FOR AMPHETAMINE, METHAMPHETAMINE, BENZOYLECGONINE, THC
Device Facts
| Record ID | K052520 |
|---|---|
| Device Name | RAPID FORSURE ONE STEP MULTIPLE DRUG (UP TO 6) SCREEN TEST DEVICE FOR AMPHETAMINE, METHAMPHETAMINE, BENZOYLECGONINE, THC |
| Applicant | Tianjin New Bay Bioresearch Co., Ltd. |
| Product Code | DJG · Clinical Toxicology |
| Decision Date | Apr 24, 2006 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.3650 |
| Device Class | Class 2 |
Indications for Use
The Forsure One Step Multiple (Up to Six) Drug Screen Test Card is a prescription assay intended for professional use in central laboratories only. It provides qualitative screening results for Amphetamine (AMP), Methamphetamine (MET), Bezoylecgonine (BEG/COC), 11-nor-Δ-9-Tetrahydrocannabinol-9-carboxylic acid (THC), Morphine (MOR/OPI) and Phencyclidine (PCP) in human urine at cut off concentrations of AMP 1000 ng/ml, MET 1000 ng/ml, BEG 300 ng/ml, THC 50ng/ml, MOR 2000 ng/ml and PCP 25ng/ml. The device may include as few as one and as many as six individual assays. For In Vitro Diagnostic Use. This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly in evaluating a preliminary positive. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.
Device Story
Single-use lateral flow immunochromatographic test card; tests human urine for drugs of abuse (AMP, MET, BEG, THC, MOR, PCP). Operator adds urine sample to cassette well; sample migrates through test strips containing monoclonal mouse antibodies. Competitive binding between drug in sample and drug-labeled conjugate determines presence of test line. Visual readout: line absence indicates positive; line presence indicates negative. Used in central laboratories by professional staff. Provides preliminary screening results; requires GC/MS confirmation for clinical decision-making. Benefits include rapid, qualitative identification of drug presence to guide further diagnostic or clinical action.
Clinical Evidence
No clinical data; bench testing only. Performance demonstrated via analytical cutoff verification and comparison to predicate device.
Technological Characteristics
Lateral flow immunochromatographic assay. Single-use cassette format. Reagents: monoclonal mouse antibodies (anti-AMP, MET, BEG, MOR, THC, PCP) and goat anti-mouse control line. Visual readout. Storage: 2–30°C. No electronic components or software.
Indications for Use
Indicated for professional use in central laboratories for qualitative screening of Amphetamine, Methamphetamine, Benzoylecgonine, THC, Morphine, and Phencyclidine in human urine. Intended for prescription use.
Regulatory Classification
Identification
An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.
Special Controls
*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
- Monitect Multiple Drug Screen MOR2000/MET/THC/COC/PCP (K004034)
Submission Summary (Full Text)
{0}
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
DEVICE ONLY TEMPLATE
A. 510(k) Number:
k052520
B. Purpose for Submission:
New device
C. Measurand:
Amphetamine, methamphetamine, benzoylecgonine, morphine, tetrahydrocannabinol (THC), and phencyclidine (PCP)
D. Type of Test:
Qualitative immunoassay
E. Applicant:
Tianjin New Bay Bioresearch Co., Ltd.
F. Proprietary and Established Names:
Forsure One Step Multiple (Up to Six) Drug Screen Test Card
G. Regulatory Information:
1. Regulation sections:
21 CFR 862.3100, 862.3610, 862.3250, 862.3640, 862.3870
2. Classification:
All class II
3. Product Codes:
DKZ, DJC, DIO, DPK, LDJ, LCM
4. Panel:
Toxicology (91)
H. Intended Use:
1. Intended use(s):
Refer to Indications for use.
2. Indication(s) for use:
The Forsure One Step Multiple (Up to Six) Drug Screen Test Card is a prescription assay intended for professional use in central laboratories only. It provides qualitative screening results for Amphetamine (AMP), Methamphetamine (MET), Bezoylecgonine (BEG/COC), 11-nor-Δ-9-Tetrahydrocannabinol-9-carboxylic acid (THC), Morphine (MOR/OPI) and Phencyclidine (PCP) in human urine at cut off concentrations of AMP 1000 ng/ml, MET 1000 ng/ml, BEG 300 ng/ml, THC 50ng/ml, MOR 2000 ng/ml
{1}
Page 2 of 15
and PCP 25ng/ml. The device may include as few as one and as many as six individual assays. For In Vitro Diagnostic Use.
This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly in evaluating a preliminary positive. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.
3. Special condition for use statement(s):
This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly in evaluating a preliminary positive. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.
Certain foods or medications may interfere with tests for amphetamines and opiates and cause false positive results.
4. Special instrument Requirements:
Not applicable. The device is a visually read single-use device.
I. Device Description:
The product is a single-use device in which one or two strips are inserted into a cassette. Each of the strips contains reagents that test for one to three drugs; therefore the device can test as few as one or as many as six drugs at a time. Operators add several drops of the sample to the sample well. The test reaction is initiated by movement of the sample through the test strip.
Description of the test antibodies: monoclonal mouse antibody against amphetamine, methamphetamine, benzoylecgonine, morphine, tetrahydrocannabinol (THC), and phencyclidine (PCP).
Description of the control line antibody: monoclonal goat anti-mouse
J. Substantial Equivalence Information:
1. Predicate device name(s):
Branan Medical Corporation Monitect Multiple Drug Screen
2. Predicate K number(s):
k004034
3. Comparison with predicate:
Both devices are for the qualitative determination of the same analyte(s) in the same matrix, and utilize the same cutoff concentration. Both are visually-read single use devices.
{2}
Page 3 of 15
The reagent formulations vary between the two devices.
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended Use | Qualitative Detection of Drugs of Abuse | Same |
| Analytes and Cutoffs | Amphetamine: 1000 ng/mL
Methamphetamine: 1000 ng/mL
Benzoylecgonine: 300 ng/mL
THC: 50 ng/mL
Phencyclidine: 25 ng/mL
Morphine: 2000 ng/mL | Amphetamine: 1000 ng/mL
Methamphetamine: 1000 ng/mL
Benzoylecgonine: 300 ng/mL
THC: 50 ng/mL
Phencyclidine: 25 ng/mL |
| Matrix | Urine | Same |
| Methodology | Lateral Flow Immunochromatographic | Same |
| Differences | | |
| Item | Device | Predicate |
| Storage Temperature | 2 – 30° C | 20 – 30° C |
**K. Standard/Guidance Document Referenced (if applicable):**
The sponsor did not reference any standards in their submission.
**L. Test Principle:**
The test employs lateral flow immunochromatographic technology.
Drug in the sample and drug-labeled conjugate (containing a chromagen) compete for antibody binding sites in the test area of the test strip. Binding of drug in the sample causes the absence of a line at the test area, i.e., a positive result. When drug is not present in the sample, the drug-labeled conjugate binds at the test line, resulting in formation of a line, i.e., a negative result. The absence or presence of the line is determined visually by the operator.
The device also has an internal process control which indicates that an adequate volume of sample has been added and that the immunochromatographic strip is intact.
**M. Performance Characteristics (if/when applicable):**
1. Analytical performance:
a. Precision/Reproducibility:
The sponsor performed a precision study in which they compared results from a single-analyte device to the same assay as part of a six-drug card. For example, single benzoylecgonine results were compared to benzoylecgonine results when included as part of a six-
{3}
Page 4 of 15
analyte device. The sponsor used one lot of product for each of the six individual assays and one lot of product for the multi-analyte assays.
Specimen description: drug free urine spiked with benzoylecgonine, $\Delta 9$ -THC, morphine, PCP, d-amphetamine, d-methamphetamine
Number of days: one day each for both single and multiple analyte devices
Replicates per day: fifteen
Lots of product used: one for multiple analyte devices, one for each single-analyte device
Number of operators: three
Operator: manufacturer staff
Testing Facility: manufacturer
Results of the study are presented below:
Benzoylecgonine Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 0 | 15 | 15/0 |
| 150 | 15 | 15/0 |
| 225 | 15 | 11/4 |
| 300 | 15 | 0/15 |
| 375 | 15 | 0/15 |
| 450 | 15 | 0/15 |
Benzoylecgonine Precision Study Results with benzoylecgonine only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 150 | 15 | 15/0 |
| 225 | 15 | 11/4 |
| 300 | 15 | 0/15 |
| 375 | 15 | 0/15 |
| 450 | 15 | 0/15 |
Tetrahydrocannabinol Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
{4}
Page 5 of 15
| 0 | 15 | 15/0 |
| --- | --- | --- |
| 25 | 15 | 15/0 |
| 37.5 | 15 | 13/2 |
| 50 | 15 | 0/15 |
| 62.5 | 15 | 0/15 |
| 75 | 15 | 0/15 |
Tetrahydrocannabinol Precision Study Results with THC only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 25 | 15 | 15/0 |
| 37.5 | 15 | 9/6 |
| 50 | 15 | 0/15 |
| 62.5 | 15 | 0/15 |
| 75 | 15 | 0/15 |
Morphine Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 0 | 15 | 15/0 |
| 1000 | 15 | 15/0 |
| 1500 | 15 | 14/1 |
| 2000 | 15 | 0/15 |
| 2500 | 15 | 0/15 |
| 3000 | 15 | 0/15 |
Morphine Precision Study Results with morphine only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 1000 | 15 | 15/0 |
| 1500 | 15 | 13/2 |
| 2000 | 15 | 0/15 |
| 2500 | 15 | 0/15 |
| 3000 | 15 | 0/15 |
Phencyclidine Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 0 | 15 | 15/0 |
{5}
Page 6 of 15
| 12.5 | 15 | 15/0 |
| --- | --- | --- |
| 18.75 | 15 | 10/5 |
| 25 | 15 | 0/15 |
| 31.25 | 15 | 0/15 |
| 37.5 | 15 | 0/15 |
## Phencyclidine Precision Study Results with phencyclidine only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 12.5 | 15 | 15/0 |
| 18.75 | 15 | 10/5 |
| 25 | 15 | 0/15 |
| 31.25 | 15 | 0/15 |
| 37.5 | 15 | 0/15 |
## Amphetamine Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 0 | 15 | 15/0 |
| 500 | 15 | 15/0 |
| 750 | 15 | 12/3 |
| 1000 | 15 | 0/15 |
| 1250 | 15 | 0/15 |
| 1500 | 15 | 0/15 |
## Amphetamine Precision Study Results with amphetamine only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 500 | 15 | 15/0 |
| 750 | 15 | 11/4 |
| 1000 | 15 | 0/15 |
| 1250 | 15 | 0/15 |
| 1500 | 15 | 0/15 |
## Methamphetamine Precision Study Results as part of a six-drug device
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
{6}
Page 7 of 15
| 0 | 15 | 15/0 |
| --- | --- | --- |
| 500 | 15 | 15/0 |
| 750 | 15 | 11/4 |
| 1000 | 15 | 0/15 |
| 1250 | 15 | 0/15 |
| 1500 | 15 | 0/15 |
Methamphetamine Precision Study Results with methamphetamine only
| Concentration of sample, ng/mL | Number of determinations | Results # Neg/ #Pos |
| --- | --- | --- |
| 500 | 15 | 15/0 |
| 750 | 15 | 12/3 |
| 1000 | 15 | 0/15 |
| 1250 | 15 | 0/15 |
| 1500 | 15 | 0/15 |
The sponsor also performed a separate Inter-Lot Reproducibility study in which they compared three different lots of the six-drug devices at 0, 50, 75, 100, 125, and 150% of the cutoff for each analyte.
Specimen description: drug free urine spiked with benzoylecgonine, Δ9-THC, morphine, PCP, d-amphetamine, d-methamphetamine
Number of days: fifteen
Replicates per day: fifteen
Lots of product used: three
Number of operators: three
Operator: manufacturer staff
Testing Facility: manufacturer
| | Lot 1 | | Lot 2 | | Lot 3 | |
| --- | --- | --- | --- | --- | --- | --- |
| | Positive | Negative | Positive | Negative | Positive | Negative |
| Amphetamine | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 75% Cutoff | 2 | 13 | 5 | 10 | 2 | 13 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| Methamphetamine | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
{7}
Page 8 of 15
| | Lot 1 | | Lot 2 | | Lot 3 | |
| --- | --- | --- | --- | --- | --- | --- |
| | Positive | Negative | Positive | Negative | Positive | Negative |
| 75% Cutoff | 3 | 12 | 4 | 11 | 4 | 11 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| Benzoylecgonine | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 75% Cutoff | 2 | 13 | 3 | 12 | 3 | 12 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| THC | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 75% Cutoff | 2 | 13 | 1 | 14 | 3 | 12 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| Morphine | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 75% Cutoff | 4 | 11 | 4 | 11 | 2 | 13 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| Phencyclidine | | | | | | |
| 0% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 50% Cutoff | 0 | 15 | 0 | 15 | 0 | 15 |
| 75% Cutoff | 1 | 14 | 1 | 14 | 3 | 12 |
| 100% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 125% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
| 150% Cutoff | 15 | 0 | 15 | 0 | 15 | 0 |
b. Linearity/assay reportable range:
Not applicable. The assay is intended for qualitative use.
c. Traceability (controls, calibrators, or method):
The device has an internal process control. Users are instructed to follow federal, state, and local guidelines when determining when to run external controls.
d. Detection limit:
{8}
Page 9 of 15
Sensitivity of this assay is characterized by validating performance around the claimed cutoff concentration of the assay, including a determination of the lowest concentration of drug that is capable of producing a positive result. This information appears in the precision section, above.
e. Analytical specificity:
Cross-reactivity was established by spiking various concentrations of similarly structured drug compounds into drug-free urine. By analyzing various concentrations of each compound the sponsor determined the concentration of the drug that produced a response approximately equivalent to the cutoff concentration of the assay. Results of those studies appear in the table(s) below:
Amphetamine
| Drug Compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| d-amphetamine | 1000 |
| l-amphetamine | 25,000 |
| d-methamphetamine | >400,000 |
| l-methamphetamine | >400,000 |
| 3,4-Methylenedioxyethylamphetamine(MDEA) | 100,000 |
| D,L 3,4-Methylenedioxymethamphetamine (MDMA) | >400,000 |
| 3,4-Methylenedioxyamphetamine (MDA) | 1200 |
Methamphetamine
| Drug Compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| d-amphetamine | 200,000 |
| l-amphetamine | 200,000 |
| d-methamphetamine | 1000 |
| 3,4-Methylenedioxyethylamphetamine(MDEA) | 500 |
| D,L 3,4-Methylenedioxymethamphetamine (MDMA) | 1000 |
| 3,4-Methylenedioxyamphetamine (MDA) | >200,000 |
Morphine
| Drug compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| 6-monoacetylmorphine | 50 |
| Codeine | 2000 |
| Heroin | 2000 |
| Hydrocodone | 20,000 |
| Hydromorphone | 5000 |
| Oxycodone | 60,000 |
| Morphine | 2000 |
{9}
Page 10 of 15
| Drug compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| Morphine-3-β-glucuronide | 2000 |
| Ethylmorphine | 50 |
Benzoylecgonine
| Compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| Benzoylecogonine | 300 |
| Cocaethylene | 50 |
| Cocaine | 300 |
Cannabinoids (THC)
| Compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| 11-Hydroxy-Δ⁹-Tetrahydrocannabinol | 2500 |
| 11-Nor-Δ⁸-Tetrahydrocannabinol carboxylic acid | 50 |
| 11-Nor-Δ⁹-Tetrahydrocannabinol carboxylic acid | 50 |
| Δ⁸-Tetrahydrocannabinol | 7500 |
| Δ⁹-Tetrahydrocannabinol | 10,000 |
| Cannabinol | 10,000 |
Phencyclidine
| Compound | Response equivalent to cutoff in ng/mL |
| --- | --- |
| Phencyclidine | 25 |
| 4-hydroxyphencyclidine | 1000 |
| Phencyclidine Morpholine | 50 |
| Tenocyclidine | 2000 |
The following compounds were evaluated for potential positive and/or negative interference with the assay. To evaluate for interference the sponsor added potentially interfering compounds to drug-free urine (to test for positive interference) and to urines at the cutoff concentration (to test for negative interference). All potential interferents were added at a concentration of 100 µg/mL. There were no deviations from the expected results.
Acetaminophen
Acetylsalicylic Acid
Amikacin
Amitriptyline
Ampicillin
Amoxicillin
Amobarbital
Amoxapine
Arterenol
Ascorbic Acid
Aspartame
Benzoic Acid
Butalbital
Caffeine
Celebrex
Chlorpheniramine
Chlorpromazine-HCL
Clobazam
Clomipramine
Cortisone
Cimetidine
Cholesterol
(-) Cotinine
Cyclobenzaprine
{10}
| Deoxyephedrine | Ibuprofen | Procaine |
| --- | --- | --- |
| Dextromethorphan | (+)/ Isoproterenol | Propanol |
| Diethylpropion | Indomathacin | Promethazine |
| Diphenylhydantoin | Lidocaine | Phentermine |
| Diphenhydramine | Lorazepam | L-Phenylephrine |
| Diovan | Meperidine | Pseudoephedrine |
| Dopamine | Methylphenidate | Quinine |
| Doxylamine | Methadone | Quinidine |
| (-) Ephedrine | Methaqualone | Ranitidine (Zantac) |
| (-) Epinephrine | Naltrexone | Riboflavin |
| (+) Epinephrine | Niacinamide | Rofecoxib |
| (+)/ Epinephrine | Nitrazepam | Sodium Salicylate |
| Erythromycin | Nordiazepam | Secobarbital |
| Ethanol | (+)/ Norephedrine | Sulindac |
| Ecgonine | (-) Nicotine | Temazepam |
| Ecgonine Methyl Ester | Nicotinic Acid | Tryptophan |
| EDDP | Pendimetrazine | Tetracycline |
| Flunitrazepam | Penicillin G | Tetrahydrozoline |
| Furosemide | d-Propoxyphene | Theophylline |
| Histamine | Hydrochlorothiazide | Thioridazine |
| 3-Hydroxytyramine | Promethazine | Trifluoperazine |
There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors.
The following endogenous compounds were evaluated for potential positive and/or negative interference with the assay. To evaluate for interference the sponsor added potentially interfering compounds to drug-free urine (to test for positive interference) and to urines at the cutoff concentration plus $25\%$ (to test for negative interference). There were no deviations from the expected results.
| Ascorbate | 300 mg/dL |
| --- | --- |
| Bilirubin | 1.0 mg/dL |
| Creatinine | 500 mg/dL |
| Glucose | 1500 mg/dL |
| Globulin | 1500 mg/dL |
| Hemoglobin | 300 mg/dL |
| Human serum albumin | 500 mg/dL |
| Potassium | 110 mEq/L |
| Sodium Chloride | 6000 mg/dL |
| Uric Acid | 23 mg/dL |
| Specific Gravity | 1.003 and 1.030 |
| pH | 4, 5, 6, 7, 8, and 9 |
{11}
Page 12 of 15
f. Assay cut-off:
The identified cutoff concentrations of the assays are the cutoff concentrations recommended for use by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, above.
2. Comparison studies:
a. Method comparison with predicate device:
Because the candidate device was compared to a reference method, GC/MS, it was not compared to a predicate device.
Sample description: Unaltered clinical urine samples were evaluated.
Sample selection: Samples were purchased from a commercial laboratory, which supplied the GC-MS concentration for all negative and positive samples.
The studies included an adequate number of samples that contained drugs near to the cutoff concentration of the assay. Approximately 10% of the study samples are evenly distributed between plus and minus 50% of the claimed cutoff concentration.
Number of study sites: one
Type of study site(s): clinical setting
Operator description: clinical site staff
Candidate Device Results vs. stratified GC/MS Values - Amphetamine
A total of 110 samples (63 negative and 47 positive) were evaluated by the candidate device and by GC/MS.
| Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 3 | 5 | 42 |
| Negative | 58 | 2 | 0 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of amphetamine found in the sample.
% Agreement among positives is 100%
% Agreement among negatives is 95%
{12}
Page 13 of 15
# Candidate Device Results vs. stratified GC/MS Values - Methamphetamine
A total of 101 samples (60 negative and 41 positive) were evaluated by the candidate device and by GC/MS.
| Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 10 | 31 |
| Negative | 55 | 5 | 0 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of methamphetamine found in the sample.
% Agreement among positives is 100%
% Agreement among negatives is 100%
# Candidate Device Results vs. stratified GC/MS Values - Benzoylecgonine
A total of 96 samples (54 negative and 42 positive) were evaluated by the candidate device and by GC/MS.
| Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 15 | 25 |
| Negative | 49 | 5 | 2 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of BE found in the sample.
% Agreement among positives is 95%
% Agreement among negatives is 100%
# Candidate Device Results vs. stratified GC/MS Values - THC
A total of 96 samples (54 negative and 42 positive) were evaluated by the candidate device and by GC/MS.
| Candidate | Less than half | Near Cutoff | Near Cutoff | High Positive |
| --- | --- | --- | --- | --- |
{13}
Page 14 of 15
| Device Results | the cutoff concentration by GC/MS analysis | Negative (Between 50% below the cutoff and the cutoff concentration) | Positive (Between the cutoff and 50% above the cutoff concentration) | (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 1 | 6 | 36 |
| Negative | 50 | 3 | 0 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of THC found in the sample.
% Agreement among positives is 100%
% Agreement among negatives is 98%
## Candidate Device Results vs. stratified GC/MS Values - Morphine
A total of 96 samples (55 negative and 41 positive) were evaluated by the candidate device and by GC/MS.
| Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 17 | 24 |
| Negative | 50 | 5 | 0 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of morphine found in the sample.
% Agreement among positives is 100%
% Agreement among negatives is 100%
## Candidate Device Results vs. stratified GC/MS Values - Phencyclidine
A total of 97 samples (56 negative and 41 positive) were evaluated by the candidate device and by GC/MS.
| Candidate Device Results | Less than half the cutoff concentration by GC/MS analysis | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- |
| Positive | 0 | 4 | 16 | 25 |
| Negative | 49 | 3 | 0 | 0 |
GC/MS values used to categorize samples in this table are based on the concentration of PCP found in the sample.
% Agreement among positives is 100%
{14}
Page 15 of 15
% Agreement among negatives is 93%
b. Matrix comparison:
Not applicable. The assay is intended for only one sample matrix.
3. Clinical studies:
a. Clinical sensitivity:
Not applicable. Clinical studies are not typically submitted for this device type.
b. Clinical specificity:
Not applicable. Clinical studies are not typically submitted for this device type.
c. Other clinical supportive data (when a and b are not applicable):
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
